Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC : ADAURA2
Tsutani, Yasuhiro (Kindai University Faculty of Medicine)
Goldman, Jonathan (University of California Los Angeles)
Dacic, Sanja (Yale School of Medicine)
Yatabe, Yasushi (National Cancer Center Hospital)
Majem Tarruella, Margarita (Institut d'Investigació Biomèdica Sant Pau)
Huang, Xiangning (Oncology Biometrics. AstraZeneca)
Chen, Allen (AstraZeneca)
van der Gronde, Toon (AstraZeneca)
He, Jie (Chinese Academy of Medical Sciences and Peking Union Medical College)
Universitat Autònoma de Barcelona

Fecha:	2023
Resumen:	Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR-TKI sensitizing and EGFR T790M resistance mutations, with demonstrated efficacy in EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC), including central nervous system (CNS) metastases. Here we present the rationale and study design for ADAURA2 (NCT05120349), which will evaluate adjuvant osimertinib vs. placebo in patients with stage IA2-IA3 EGFRm NSCLC, following complete tumor resection. ADAURA2 is a phase III, global, randomized, double-blind, placebo-controlled study. Patients will be adults aged ≥18 years with resected primary nonsquamous NSCLC stage IA2 or IA3 and central confirmation of an EGFR exon 19 deletion or L858R mutation. Patients will be stratified by pathologic risk of disease recurrence (high vs. low), EGFR mutation type (exon 19 deletion vs. L858R) and race (Chinese Asian vs. non-Chinese Asian vs. non-Asian), and randomized 1:1 to receive osimertinib 80 mg once daily (QD) or placebo QD until disease recurrence, treatment discontinuation, or a maximum treatment duration of 3 years. The primary endpoint of this study is disease-free survival (DFS) in the high-risk stratum. Secondary endpoints include DFS in the overall population, overall survival, CNS DFS, and safety. Health-related quality of life and pharmacokinetics will also be evaluated. Study enrolment began in February 2022 and interim results of the primary endpoint are expected in August 2027.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Adjuvant ; Early-stage ; Resectable ; Targeted therapy ; Tyrosine kinase inhibitor
Publicado en:	Clinical Lung Cancer, Vol. 24 Núm. 4 (june 2023) , p. 376-380, ISSN 1938-0690

DOI: 10.1016/j.cllc.2023.02.002
PMID: 36872181

5 p, 553.6 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados